Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Hartmut Beck, Tobias Thaler, Daniel Meibom, Mark Meininghaus, Hannah Jörißen, Lisa Dietz, Carsten Terjung, Michaela Bairlein, Clemens-Jeremias von Bühler, Sonja Anlauf, Chantal Fürstner, Timo Stellfeld, Dirk Schneider, Kersten M. Gericke, Thomas Buyck, Kai Lovis, Uwe Münster, Johanna Anlahr, Elisabeth Kersten, Guillaume Levilain, Virginia Marossek, Raimund Kast
Abstract
efficacy in a preclinical animal model of lung fibrosis, thus paving the way for a new treatment option in IPF.
Topics & Concepts
Idiopathic pulmonary fibrosisPirfenidoneNintedanibAntagonistPharmacologyIn vivoLungFibrosisPulmonary fibrosisProstaglandinBioavailabilityReceptor antagonistChemistryMedicineInternal medicineReceptorBiologyBiotechnologyInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisRespiratory and Cough-Related ResearchPeptidase Inhibition and Analysis